AbbVie (NYSE:ABBV) Shares Down 1% - Should You Sell?

Key Points

• AbbVie shares fell 1% after the FDA approved Juvmo (tavapadon), an oral Parkinson’s treatment expected to launch in October. The approval expands AbbVie’s neuroscience portfolio and could eventually support a billion-dollar product, though the initial rollout may be gradual.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $272.66 versus the recent price near $263.54. Several firms recently raised their targets to as high as $300.
• AbbVie reported quarterly earnings and revenue above expectations, with revenue up 10.2% year over year, and declared a quarterly dividend of $1.73, implying a 2.6% yield. However, the company’s high payout ratio and recent insider share sale are potential investor considerations.

Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) were down 1% on Tuesday. The stock traded as low as $261.52 and last traded at $263.5410. 3,946,828 shares changed hands during mid-day trading, a decline of 39% from the average daily volume of 6,468,157 shares. The stock had previously closed at $266.28.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA approved Juvmo (tavapadon), AbbVie’s once-daily oral treatment for adults with Parkinson’s disease. Juvmo is the first and only selective D1/D5 receptor agonist approved for the condition, and Phase 3 data showed improvements in motor control, daily functioning and “on” time without troublesome dyskinesia. The drug is scheduled to launch in the U.S. in October and could address a Parkinson’s market estimated at more than $5 billion. U.S. FDA Approves AbbVie’s Juvmo
• Positive Sentiment: The approval validates AbbVie’s $8.7 billion Cerevel Pharmaceuticals acquisition and expands its neuroscience portfolio beyond its established immunology and aesthetics franchises. Analysts have suggested Juvmo could eventually become a billion-dollar product. AbbVie’s Cerevel buyout delivers
• Positive Sentiment: AbbVie partnered with Valkai to apply artificial intelligence across targeted clinical-development activities. The collaboration is intended to strengthen AbbVie’s AI capabilities, improve development efficiency and accelerate the delivery of new medicines, supporting longer-term pipeline growth. AbbVie partners with Valkai
• Neutral Sentiment: Brokerages’ average price target is approximately $272.66, modestly above the recent trading level, indicating measured upside expectations rather than a major near-term repricing. AbbVie average target price
• Negative Sentiment: ABBV’s decline following the Juvmo announcement indicates a possible “sell-the-news” reaction. Investors may also be concerned that management expects a slow initial launch, with meaningful revenue contribution dependent on physician adoption, market access and gradual patient uptake. AbbVie stock drops after Juvmo approval

Wall Street Analysts Forecast Growth

ABBV has been the topic of several analyst reports. Wall Street Zen lowered shares of AbbVie from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 5th. Erste Group Bank upgraded AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. BMO Capital Markets upped their target price on shares of AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Guggenheim upped their price target on AbbVie from $261.00 to $288.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Finally, Wolfe Research upgraded AbbVie from a "peer perform" rating to an "outperform" rating and raised their price objective for the company from $235.00 to $300.00 in a report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $272.66.

AbbVie Stock Performance

The company has a market capitalization of $465.62 billion, a P/E ratio of 74.45, a PEG ratio of 1.19 and a beta of 0.29. The stock's fifty day moving average price is $257.41 and its 200-day moving average price is $233.59.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the business earned $2.97 earnings per share. The business's revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie's dividend payout ratio is 195.48%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Institutional Trading of AbbVie

Several hedge funds and other institutional investors have recently modified their holdings of the stock. QRG Capital Management Inc. grew its stake in AbbVie by 8.8% in the 2nd quarter. QRG Capital Management Inc. now owns 301,006 shares of the company's stock valued at $75,745,000 after buying an additional 24,245 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in AbbVie by 7.6% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 89,324 shares of the company's stock worth $22,478,000 after acquiring an additional 6,327 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in shares of AbbVie by 0.7% during the second quarter. Envestnet Asset Management Inc. now owns 4,886,670 shares of the company's stock worth $1,229,679,000 after acquiring an additional 33,103 shares during the period. State Street Corp grew its position in shares of AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company's stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. Finally, Premier Financial Group acquired a new position in shares of AbbVie in the second quarter valued at approximately $250,000. Institutional investors own 70.23% of the company's stock.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.